Conclusion of Valeant's (VRX) Ad Hoc Committee Review is Positive Development - Moody's
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Allergan (AGN) Could Move on Valeant's (VRX) Bausch + Lomb Unit if Pfizer (PFE) Deal Fails - Analyst
April 5, 2016 3:47 PM EDTBTIG issued brief commentary on Allergan (NYSE: AGN) following the U.S. Treasury's tax inversion actions on Monday night.
Analyst Timothy Chiang commented on potential routes for Allergan if its deal with Pfizer (NYSE: PFE)... More
Valeant (VRX) Could Be on the Verge of a Significant Inflection Point - BMO Capital
April 5, 2016 10:09 AM EDTBMO Capital analyst Alex Arfaei said Valeant Pharmaceuticals (NYSE: VRX) could be on the verge of a significant inflection point after the ad hoc committee of the board of directors believes that its review of various Philidor and related accounting matters is complete and that it has not identified any additional items that would require restatements beyond those required by matters previously disclosed. The company intend to file its Form 10-K on or before April 29. The firm maintained its Market Perform rating and price target of $66.00.
Arfaei views the news as positive: "Our... More
Valeant Pharma's (VRX) Ad Hoc Committee Completes Review; No Additional Items for Restatement Identified
April 5, 2016 8:49 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that the ad hoc committee of the board of directors (the "Ad Hoc Committee") believes that its review of various Philidor and related accounting matters is complete, and that it has not identified any additional items that would require restatements beyond those required by matters previously disclosed.
Given the completion of the review, Valeant's Board has determined to dissolve the Ad Hoc Committee and that the 12... More
Valeant Pharma (VRX) said to terminate Addyi sales force in reorganization - Bloomberg
April 4, 2016 5:07 PM EDTValeant Pharma (NYSE: VRX) said to terminate Addyi sales force in reorganization, according to Bloomberg.
Valeant said it has received increasing feedback from doctors that we have too many people calling on them to discuss closely related product.
... MoreSome Valeant Pharma (VRX) Creditors Said Against Proposal to Relax Loan Pact
April 4, 2016 3:53 PM EDT(Updated - April 4, 2016 4:00 PM EDT)
Some Valeant Pharma (NYSE: VRX) creditors said to resist proposal to relax loan pact, according to Bloomberg. Some lenders are said looking for higher fees and rates, sources noted.
UPDATE - Valeant... More
